Association between lipoprotein-associated phospholipase A2 levels and risk of recurrent cerebrovascular events in patients with ischemic stroke: A systematic review and meta-analysis.

J Stroke Cerebrovasc DisAug 8, 2026 (epub)
Clinical ResearchNeurologyCardiology

Xiaofeng Zhang, Ji Li, Qiuping Xu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the relationship between lipoprotein-associated phospholipase A2 (Lp-PLA2) levels and recurrent cerebrovascular events in 2,527 patients with ischemic stroke. The analysis found that higher Lp-PLA2 levels were associated with a significantly increased risk of recurrent events, with a pooled relative effect estimate of 2.99 (95% CI 2.24-3.99; P < 0.001).

Key findings

  • Higher Lp-PLA2 levels were associated with a pooled relative effect estimate of 2.99 for recurrent cerebrovascular events.
  • Excluding one study, the association remained stable with a pooled estimate of 2.76.
  • Each 1-SD increase in Lp-PLA2 was linked to a pooled odds ratio of 2.62 for recurrent events.

Why it matters

Understanding the association between Lp-PLA2 levels and recurrent cerebrovascular events can help clinicians identify patients at higher risk and potentially guide secondary prevention strategies after ischemic stroke.

Source

PubMed · PMID 42570806

Published in J Stroke Cerebrovasc Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.